Actoplus Met: Uses, Dosage & Safety Information

Actoplus Met

Actoplus Met

Actoplus Met

Pioglitazone + Metformin
Brand pill pairing an insulin sensitiser with a biguanide for grown-ups whose blood sugar runs high, cleared in 2005. It lowered average glucose more than either part alone, yet carries warnings for fluid-driven heart failure and rare but dangerous acid build-up in the blood.
  • ActiveIngredient: Pioglitazone + Metformin
  • DosageForm: Tablet
  • Dosage: 15 mg/850 mg
  • Indications: Type 2 diabetes mellitus
  • Manufacturer: Takeda
  • Storage: 25°C (77°F); excursions 15–30°C
  • Drug Status: Prescription Only

What is Actoplus Met?

Actoplus Met is Takeda’s tablet combining pioglitazone, a thiazolidinedione that makes tissues more sensitive to insulin, with metformin, a biguanide, to improve blood sugar control alongside diet and exercise in adults with type 2 diabetes. It is not for type 1 diabetes or diabetic ketoacidosis. It carries two boxed warnings: pioglitazone can cause or worsen heart failure, and metformin can rarely cause fatal lactic acidosis. It is contraindicated in serious heart failure, severe kidney impairment and metabolic acidosis.1

FDA-approved brand, prescription only
Actoplus Met (NDA 021842) was approved in August 2005; one strength remains a prescription product, while the other strength and the extended-release Actoplus Met XR (NDA 022024) are listed as discontinued.2

Approved products and generic therapeutic-equivalence ratings are listed in the FDA Orange Book.3

The two ingredients work differently: pioglitazone activates the PPAR-gamma receptor to improve insulin sensitivity in muscle, fat and liver, while metformin reduces glucose production by the liver and its absorption from the gut.1

In a 24-week trial of 600 adults on diet and exercise alone, the combination lowered HbA1c by 1.8 points, versus 1.0 with either drug alone, and 64% reached an HbA1c of 7% or less.1

Pioglitazone causes fluid retention, which explains the dose-related ankle swelling and weight gain seen in trials and the heart-failure warning.

Because pioglitazone can restore ovulation in some women who are not ovulating, the possibility of unintended pregnancy is discussed before treatment.

Actoplus Met is one of the diabetes medicines; Duetact pairs pioglitazone with glimepiride instead.

How to Take Actoplus Met

Take it with meals

Take Actoplus Met with meals to reduce stomach upset from the metformin component; if you miss a dose, do not double the next one.1

Weight gain and swelling

Report rapid weight gain, breathlessness or swelling of the ankles or legs, which can signal fluid retention or heart failure.

Signs of lactic acidosis

Seek urgent care for unusual muscle pain, trouble breathing, unusual sleepiness, stomach pain or feeling cold or dizzy.

Before scans with contrast

Tell the team before any imaging with iodinated contrast dye; you may need to pause Actoplus Met.

Low blood sugar

If you also use insulin or a sulfonylurea, your doctor may lower their dose to reduce the risk of low blood sugar.

Blood in the urine

Tell your doctor about blood in the urine, urgency or pain on passing urine, as pioglitazone may increase the risk of bladder cancer.

Eye checks

Keep up regular eye examinations and report any sudden change in vision.

Bones

Women taking pioglitazone have more fractures; discuss bone health with your doctor.

What Are the Side Effects of Actoplus Met?

In the 24-week combination trial, diarrhoea and headache were the reactions reported in at least 5% of people on Actoplus Met; in longer pioglitazone trials, swelling, weight gain and upper respiratory infections were common.

Actoplus Met: Trial Reactions
FrequencyEffectNotes
Very common — 9.0% (pioglitazone 2.6%, metformin 15.3%)Diarrhoea24-week combination trial
Common — 5.5% (pioglitazone 2.6%, metformin 4.8%)Headache24-week combination trial
Common — 6.0% (placebo add-on 2.5%)Oedema with pioglitazone added to metformin16-week trial
Very common — 13.9% at the top pioglitazone doseOedema with pioglitazone added to metformin24-week trial
Common — 1.3% (placebo 0.6%)Heart failure leading to withdrawalPROactive, 34.5 months
Frequency not established (labelled)Lactic acidosis, liver failure, bladder cancer, macular oedema, fractures in womenWarnings

Source: 1

Seek immediate medical attention if:
  • Breathlessness, rapid weight gain or swelling
  • Muscle pain, trouble breathing, unusual sleepiness or feeling cold (possible lactic acidosis)
  • Dark urine, yellow skin or eyes, or upper-right abdominal pain
  • Blood in the urine or sudden vision changes
Clinical details

In the PROactive outcome trial of pioglitazone, with mean follow-up of 34.5 months, oedema occurred in 26.7% versus 15.3% on placebo and heart failure in 8.1% versus 6.1%.

What is Actoplus Met Used For?

Actoplus Met is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes; it is not intended for type 1 diabetes or diabetic ketoacidosis.1

Starting dose

The starting dose depends on what the person already takes: someone on neither drug starts at one tablet daily, while people already on metformin, pioglitazone or both switch to the closest matching dose, then titrate gradually up to the labelled maximum. People with mild heart failure start at the lowest dose and are watched for fluid retention.

Trial results

In 600 adults inadequately controlled with diet and exercise, HbA1c fell by 1.8 points with the combination after 24 weeks versus 1.0 with either pioglitazone or metformin alone, and fasting glucose fell by roughly twice as much as with either drug alone.1

Kidney and liver

Kidney function is checked before starting: it is contraindicated with an eGFR below 30, not started between 30 and 45, and stopped if eGFR falls below 30. Liver tests are taken before starting, and it is advised against in liver impairment.

Children and older adults

Safety and effectiveness in children have not been established, and kidney function is assessed more often in older adults.

Interactions Alcohol:

Unsafe
Excessive alcohol increases the risk of metformin-associated lactic acidosis.

Interactions Other Medications:

Use with caution
Gemfibrozil, rifampin, topiramate, ranolazine, cimetidine, insulin and sulfonylureas need care; see Interactions.

Special Groups Pregnancy:

Consult your doctor
Data on use in pregnancy are limited; discuss with your doctor.

Special Groups Breastfeeding:

Use with caution
No human milk data exist for pioglitazone; it is present in rat milk.

Special Groups Elderly:

Use with caution
Kidney function is assessed more frequently in older adults.

Special Groups Children:

Unsafe
Safety and effectiveness in children have not been established.

Effects on Activities Driving:

Use with caution
Low blood sugar is possible with insulin or sulfonylureas; check your sugar before driving.

Effects on Activities Operating Machinery:

Use with caution
Do not operate dangerous machinery if you feel shaky or light-headed.

Two boxed warnings in one tablet

Actoplus Met combines the heart-failure warning of pioglitazone with the lactic-acidosis warning of metformin, so fluid status and kidney function are both monitored.1

Bladder cancer and fractures

Pioglitazone may increase the risk of bladder cancer and is not used with active bladder cancer; fractures, mainly in women, were also more frequent.

Brand and components

Generic versions must contain the same active ingredients and be bioequivalent to the reference product.4

Where it comes from

Actoplus Met is prescription-only in the US; the FDA’s BeSafeRx guidance lists four signs of a lawful pharmacy website.5

Critical Warnings for Actoplus Met Use

Contraindications

Actoplus Met is contraindicated when NYHA class III or IV heart failure is present at the start of treatment, with an eGFR below 30, with serious hypersensitivity to either ingredient, and in metabolic acidosis including diabetic ketoacidosis.1

Heart failure (boxed warning)

Pioglitazone can cause or worsen heart failure through fluid retention, especially with insulin; patients are watched after starting and dose increases.

Lactic acidosis (boxed warning)

Metformin-associated lactic acidosis is rare but can be fatal; risk rises with kidney impairment, age 65 or over, contrast imaging, surgery, hypoxia, excessive alcohol and liver impairment.

Liver and bladder

Fatal liver failure has been reported, so liver tests are checked; pioglitazone may increase bladder cancer risk and is not used with active bladder cancer.

Bone, eye and vitamin B12

Fractures are more frequent in women, macular oedema has been reported, and metformin can lower vitamin B12 levels.

See Interactions for the full list of drug combinations.

Dosage

Actoplus Met Products
FormulationActive IngredientsClinical Note
Tablets (pioglitazone/metformin)Actoplus Met15/850 mg
Not on either drugActoplus MetOne tablet once daily
Maximum daily doseActoplus MetPioglitazone 45 mg + metformin 2,550 mg
Mild heart failure (NYHA I–II)Actoplus Met15/850 mg once daily; monitor fluid
Kidney: eGFR <30Actoplus MetContraindicated
Kidney: eGFR 30–45Actoplus MetDo not start; reassess if already on it
Liver impairmentActoplus MetAvoid
With gemfibrozilActoplus MetLimit to 15/850 mg daily

Source: 1

Exceeding the dose
One reported pioglitazone overdose, taken over 11 days, caused no symptoms. Metformin overdoses above 50 grams have been reported, with lactic acidosis in about a third of cases; metformin is removed by haemodialysis, which may help in suspected overdose.1

Marketed strengths and their labelers are listed in the FDA National Drug Code Directory.6

What Does Actoplus Met Interact With?

Interactions by Severity
Interacting SubstanceEffect and RiskSeverityDocumentation
Gemfibrozil (strong CYP2C8 inhibitor)Higher pioglitazone exposure; dose limitMajorGood — labelled
Rifampin (CYP2C8 inducer)Lower pioglitazone levelsModerateGood — labelled
Carbonic anhydrase inhibitors (e.g. topiramate)Higher lactic acidosis riskModerateGood — labelled
Ranolazine, dolutegravir, cimetidineMetformin accumulationModerateGood — labelled
Insulin, sulfonylureasHypoglycaemia; lower their doseModerateGood — labelled
Alcohol (excessive)Lactic acidosis riskMajorGood — labelled

Source: 1

Actoplus Met is a tablet for adults with type 2 diabetes that combines two medicines. Pioglitazone improves the body’s response to insulin, and metformin reduces glucose production by the liver. In a 24-week trial of 600 adults, HbA1c fell by 1.8 points on the combination versus 1.0 with either drug alone, and 64% reached an HbA1c of 7% or less.
Actoplus Met carries two boxed warnings, one for each ingredient. Pioglitazone can cause or worsen heart failure through fluid retention, so it is not started in NYHA class III or IV heart failure. Metformin can rarely cause fatal lactic acidosis, especially with kidney impairment, contrast scans or heavy drinking. Report rapid weight gain, breathlessness, muscle pain or unusual sleepiness promptly.
Yes. Actoplus Met is taken with meals to reduce stomach side effects from the metformin component; in the 24-week trial, diarrhoea affected 9.0% on the combination versus 15.3% on metformin alone. The starting dose depends on what you already take, and the dose is increased gradually. If you miss a dose, do not double the next one.
It depends on kidney function. Actoplus Met is contraindicated when eGFR is below 30, is not started when eGFR is between 30 and 45, and is stopped if eGFR falls below 30. Kidney function is checked before starting and more often in older adults. Tell the team before any scan with iodinated contrast dye, because the tablets may need to be paused.
No. The extended-release Actoplus Met XR is listed as discontinued, as is the lower-metformin strength of ordinary Actoplus Met; one strength remains a prescription product. People who need a different balance of the two drugs may take pioglitazone and metformin as separate tablets. If you take gemfibrozil, the pioglitazone part is limited, so tell your prescriber.

Evidence scope

What we know
  • The combination lowered HbA1c by 1.8 points versus 1.0 with either drug alone.
  • 64% reached an HbA1c of 7% or less on the combination.
  • Diarrhoea affected 9.0% on the combination versus 15.3% on metformin alone.
  • It is contraindicated with an eGFR below 30.
What remains uncertain
  • Safety and effectiveness in children.
  • Whether pioglitazone or metformin passes into human milk in meaningful amounts; data are limited.
  • Whether long-term combination use changes cardiovascular outcomes; no combination outcome trial exists.

Source: 1

What has been reported to the FDA

Reports to the FDA naming pioglitazone are summarised on the Actos page, and those naming metformin on the metformin page.7

Who was this medicine studied in?

A 24-week trial randomised 600 adults to the combination or either component, and pioglitazone has been studied in over 8,500 patients, including 2,605 in the PROactive outcome trial.1

Who this is and is not appropriate for

Not for type 1 diabetes, diabetic ketoacidosis, NYHA class III–IV heart failure at the start, eGFR below 30, metabolic acidosis, or active bladder cancer.

Adults with type 2 diabetes who need both pioglitazone and metformin and have no serious heart failure or kidney impairment.

Where to report and verify

Routing to Official Registries
What you needWhere to go
Report a side effectFDA MedWatch
Pregnancy-specific dataMotherToBaby
Full prescribing informationDailyMed
Verify a pharmacy websiteFDA BeSafeRx · LegitScript

References

  1. FDA Prescribing Information, ACTOPLUS MET (pioglitazone and metformin HCl) tablets (Takeda; NDA 021842)
    Revised 2026-08 · Accessed 2026-10-24
    Used for: boxed warnings, indication, dosing by regimen and kidney function, contraindications, warnings, adverse reactions incl. PROactive, interactions, specific populations, overdose, clinical studies.
    dailymed.nlm.nih.gov — ACTOPLUS MET SPL
  2. Drugs@FDA
    Record accessed 2026-10-24
    Used for: application and marketing status.
    accessdata.fda.gov — Drugs@FDA
  3. FDA Orange Book
    Accessed 2026-10-24
    Used for: reference and generic listings.
    accessdata.fda.gov — Orange Book
  4. FDA — Generic Drugs: Questions & Answers
    Accessed 2026-10-24
    Used for: requirements for generic equivalence (same active ingredient, strength, bioequivalence).
    fda.gov — Generic Drugs Q&A
  5. FDA BeSafeRx — signs of a safe pharmacy website (flyer)
    Accessed 2026-10-24
    Used for: four signs of a lawful pharmacy website.
    fda.gov — BeSafeRx
  6. FDA National Drug Code Directory
    Directory accessed 2026-10-24
    Used for: marketed products and strengths.
    accessdata.fda.gov — NDC Directory
  7. FDA Adverse Event Reporting System (openFDA)
    Data cut 2026-07-30 · Accessed 2026-10-24
    Used for: report totals and the ten most frequent terms.
    open.fda.gov — drug adverse event API

How this page was sourced

Clinical, dosing and safety facts come from the current FDA prescribing information for Actoplus Met.

Approval data come from Drugs@FDA; report summaries are on the Actos and metformin pages.

Disclaimer: The information on this site is provided for informational purposes only and is not medical advice. It does not replace professional medical consultation, diagnosis, or treatment. Do not self-medicate based on the information presented on this site. Always consult with a doctor or other qualified healthcare professional before making any decisions about your health.

Medicine graph

FDA-approved uses

Boxed warning

  • WARNING: CONGESTIVE HEART FAILURE and LACTIC ACIDOSIS

Contraindications (FDA label)

  • Established NYHA Class III or IV heart failure at the time of ACTOPLUS MET initiation.
  • Severe renal impairment (eGFR below 30 mL/min).
  • Acute or chronic metabolic acidosis, including diabetic ketoacidosis.

FDA label: NDA021842